Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

The country has recorded a surge of hepatitis cases, and the alarming situation has called for better clarity in ...

Learn about 5 liver infections that can hide in your body for decades without symptoms. Discover warning signs and prevention ...

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus: North Chicago Saturday, June 14, 2025, 11:00 Hrs [IST] AbbVie announced tha ...

A viral reel by a Mumbai-based doctor claims that threading a common beauty procedure can increase one’s risk of hepatitis B infection Here’s what our expert has to say ...

The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc’s (NYSE:ABBV) Mavyret ...

hepatitis C and hepatitis D usually cause chronic disease, liver cancer and cirrhosis, whereas hepatitis A and hepatitis E cause acute disease but may lead to more serious complications in certain ...

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for a label expansion for MAVYRET ...